Investigating Gene Therapy for Inherited Hearing Loss
Prevalence of Hearing Loss and Genetic Factors
A recent study focused on the potential of gene therapy as a treatment for inherited hearing loss. Globally, approximately 466 million individuals experience hearing loss, with 60% attributed to genetic factors. More than 120 genes have been linked to hereditary deafness, many of which contain variants found only in specific populations. Presently, treatments for hearing loss primarily consist of cochlear implants and sound amplification devices, while established methods involving cell, gene therapy, or pharmacological interventions remain unavailable.
Research Team and Methodology
The research team from Tel Aviv University in Israel explored gene therapy’s effectiveness in addressing hearing loss. Prior studies indicated that variations in the SYNE4 gene (Spectrin Repeat Containing Nuclear Envelope Family Member 4) are responsible for hearing loss in humans. Mice genetically engineered to lack SYNE4 exhibit degeneration of nuclei in outer hair cells, which are crucial for hearing. These mice, referred to as Syne4-knockout mice, served as a model for evaluating gene therapy impacts.
To conduct the study, researchers utilized a synthetic adeno-associated virus (AAV) to deliver the SYNE4 gene into the inner ears of neonatal mice. AAVs are favored for gene therapeutic research due to their minimal immune response. Specifically, AAV9-PH.B was selected, as it has been previously validated for effective gene transfer to inner and outer hair cells in both mice and non-human primates.
Injection and Results
Using a specialized binocular to target the posterior-semicircular canal (PSCC), the team injected the AAV into the inner ear canals of neonatal mice. Following recovery, the treated mice underwent a series of auditory tests, cued fear conditioning, and balance assessments. Significant findings included the correction of behavioral responses linked to auditory cues in the treated mice. Furthermore, improvements were noted in the survival and structural integrity of outer hair cells post-treatment. These results imply that gene therapy targeting SYNE4 mutations could potentially benefit humans suffering from inherited deafness.
Study Limitations
Despite these promising outcomes, the study faced limitations, particularly the reliance on mice as a model organism. The onset of deafness varies among species; in Syne4-knockout mice, hearing deteriorates more rapidly compared to humans, who typically exhibit deafness after birth. This discrepancy may influence the timing of gene therapy application. Additionally, although no adverse effects were observed in the treated mice, careful monitoring of physiological responses is essential before progressing to human clinical trials.
Conclusion and Future Directions
This research underscores the significance of advancing gene therapy for hearing loss and presents a potential strategy for developing effective treatments. However, challenges remain due to the genetic diversity influencing deafness and the physiological differences between mice and humans. Further studies are necessary to enhance understanding of the genetic underpinnings of hearing loss and refine therapeutic approaches for inherited deafness.
Source: Taiber S, Cohen R, Yizhar-Barnea O, Sprinzak D, Holt JR, Avraham KB. Neonatal AAV gene therapy rescues hearing in a mouse model of SYNE4 deafness. EMBO Mol Med. 2020 Dec 22:e13259. doi: 10.15252/emmm.202013259. Epub ahead of print. PMID: 33350593.